Cell News and Research

RSS

Myomatrix 2012 conference to take place from April 22-24

The nation's leading scientists and clinicians exploring treatment breakthroughs for congenital muscular dystrophy will convene April 22-24 on the campus of the University of Nevada, Reno, where research by Dean Burkin has led to a potential therapy.

19 Apr 2012

Ten tips to avoid or treat common medical problems in the outdoors

"Good fortune favors the well prepared," says Paul S. Auerbach, MD, a founder and past President of the Wilderness Medical Society and editor of Wilderness Medicine, 6th Edition, recently published by Elsevier. With some advance reading, individuals planning vacations or outdoor excursions can become familiar with adverse situations and be prepared to handle them.

19 Apr 2012

New genetic signature may predict NSCLC patients at risk of relapse

A new genetic signature identified by Spanish researchers may provide doctors with robust and objective information about which patients with early stage lung cancer are at low or high risk of relapse following surgery, investigators report at the 3rd European Lung Cancer Conference in Geneva. Their work also opens new avenues for immunotherapy for lung cancer.

19 Apr 2012

BCCA, UBC scientists identify new breast cancer genes

Scientists at the BC Cancer Agency and University of British Columbia have identified new breast cancer genes that could change the way the disease is diagnosed and form the basis of next-generation treatments.

19 Apr 2012

New PBC tool for prioritizing laboratory-based CD-4 cell count testing

One of the major problems that has slowed progress toward universal access to life-saving antiretroviral therapy (ART) to treat AIDS in developing nations has been limited availability of laboratories and trained medical staff to conduct blood tests of immune system CD-4 T-cell levels that indicate when to start ART.

18 Apr 2012

Tengion completes FDA Pre-IND meeting for Neo-Kidney Augment preclinical program

Tengion, Inc., a leader in regenerative medicine, today announced that it recently completed a successful Pre-IND meeting with the U.S. Food and Drug Administration (FDA) for its lead preclinical program, the Neo-Kidney Augment.

18 Apr 2012

Combined, complimentary therapies maximize NSC transplantation benefits for spinal cord repair

Combined, complimentary therapies have the ability to maximize the benefits of neural stem cell (NSC) transplantation for spinal cord repair in rat models, according to a study carried out by a team of Korean researchers who published in a recent issue of Cell Transplantation.

18 Apr 2012

US DoD awards UC researchers $3.7M grant to study circadian rhythms

Researchers from the University of Cincinnati (UC) have received a four-year, $3.7 million grant from the U.S. Department of Defense for investigations into circadian rhythms that could lead to enhanced understanding of disease treatments, trauma care and human combat performance.

18 Apr 2012

Study demonstrates how Parkinson's disease protein can spread in patient's brain

Last year, researchers from the Perelman School of Medicine at the University of Pennsylvania found that small amounts of a misfolded brain protein can be taken up by healthy neurons, replicating within them to cause neurodegeneration. The protein, alpha-synuclein (a-syn), is commonly found in the brain, but forms characteristic clumps called Lewy bodies, in neurons of patients with Parkinson's disease (PD) and other neurodegenerative disorders.

18 Apr 2012

Genetically modified mouse mimics key features of Charcot-Marie-Tooth disease

A team of scientists from the University of Missouri created a genetically modified mouse that mimics key features of Charcot-Marie-Tooth disease, an inherited neuromuscular disease affecting approximately 150,000 people in the United States.

18 Apr 2012

NSCLC drug regimen approved in 2006 does not improve survival for older patients

Analysis of a drug regimen approved by the F.D.A. in 2006 for the treatment of non-small cell lung cancer (bevacizumab added to the standard chemotherapy regimen carboplatin and paclitaxel) finds Medicare insured patients age 65 years and older who received this regimen did not have improved survival compared to patients who received the standard treatment of carboplatin and paclitaxel alone, according to a study in the April 18 issue of JAMA.

18 Apr 2012

Kaposi's sarcoma-associated herpesvirus senses and reacts to host cell's impending death

A research team led by Children's National Medical Center has identified a trigger that causes latent Kaposi's sarcoma-associated herpesvirus (KSHV) to rapidly replicate itself. KSHV causes Kaposi's sarcoma, primary effusion lymphoma, and other cancers that commonly affect immunocompromised patients, including those with AIDS.

18 Apr 2012

Engineered particles tied to penetratin discover, deliver ligands for mitochondria, ribosomes

Scientists who developed a technology for identifying and targeting unique protein receptor ZIP Codes on the cellular surface have found a way to penetrate the outer membrane and deliver engineered particles - called iPhage - to organelles inside the cell.

18 Apr 2012

Bevacizumab added to chemotherapy for NSCLC does not improve survival in elderly patients

Adding the drug bevacizumab (Avastin) to the standard chemotherapy regimen for non-small cell lung cancer (NSCLC) - an approach approved by the FDA in 2006 - did not lead to significantly increase survival rates for patients over the age of 65 enrolled in Medicare, a new study by Dana-Farber Cancer Institute researchers has found.

18 Apr 2012

Failure rate of PIP silicone breast implants could be as high as 33.8%

New research published in the Journal of Plastic, Reconstructive and Aesthetic Surgery suggests that the failure rate of silicone breast implants manufactured by Poly Implant Prosth-se (PIP) could be as high as 33.8%.

18 Apr 2012

Access reports positive interim results from MuGard Phase 4 clinical trial in oral mucositis

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology and oncology supportive care, announced interim results from its ongoing MuGard Phase 4 clinical trial in oral mucositis.

18 Apr 2012

Bruker introduces new products at Analytica 2012

At Analytica 2012, Bruker today announced several new product introductions for the research, industrial and applied markets, designed to deliver confident analyses with increased sensitivity, specificity and productivity, and to push the boundaries of advanced molecular and materials research applications.

18 Apr 2012

Idera commences IMO-3100 Phase 2 clinical trial for psoriasis

Idera Pharmaceuticals, Inc. today announced the treatment of the first patient in a Phase 2 clinical trial of IMO-3100, the Company's lead Toll-like receptor (TLR) inhibitor for the treatment of autoimmune diseases, in patients with moderate to severe plaque psoriasis.

18 Apr 2012

Promising anti-diabetic substance found in liquorice root

It provides the raw material for liquorice candy, calms the stomach and alleviates diseases of the airways: liquorice root. Chosen as the "Medicinal plant 2012", the root has been treasured in traditional healing since ancient times. Researchers at the Max Planck Institute for Molecular Genetics in Berlin have now discovered that liquorice root also contains substances with an anti-diabetic effect.

18 Apr 2012

Intervertebral disc repair phase 2 trial update from Mesoblast

Global regenerative medicine company Mesoblast Limited (ASX:MSB) has announced that its Phase 2 clinical trial investigating the use of allogeneic, or off-the-shelf, Mesenchymal Precursor Cells (MPCs) for non-surgical restoration of degenerated intervertebral discs and treatment of low back pain has enrolled 50% of the total study patients. This rapid rate of enrolment attests to the major unmet medical need and to the relative simplicity of Mesoblast’s non-surgical procedure. Mesoblast expects to complete full enrolment by early third quarter.

17 Apr 2012

Cell News and Research

Myomatrix 2012 conference to take place from April 22-24

Ten tips to avoid or treat common medical problems in the outdoors

New genetic signature may predict NSCLC patients at risk of relapse

BCCA, UBC scientists identify new breast cancer genes

New PBC tool for prioritizing laboratory-based CD-4 cell count testing

Tengion completes FDA Pre-IND meeting for Neo-Kidney Augment preclinical program

Combined, complimentary therapies maximize NSC transplantation benefits for spinal cord repair

US DoD awards UC researchers $3.7M grant to study circadian rhythms

Study demonstrates how Parkinson's disease protein can spread in patient's brain

Genetically modified mouse mimics key features of Charcot-Marie-Tooth disease

NSCLC drug regimen approved in 2006 does not improve survival for older patients

Kaposi's sarcoma-associated herpesvirus senses and reacts to host cell's impending death

Engineered particles tied to penetratin discover, deliver ligands for mitochondria, ribosomes

Bevacizumab added to chemotherapy for NSCLC does not improve survival in elderly patients

Failure rate of PIP silicone breast implants could be as high as 33.8%

Access reports positive interim results from MuGard Phase 4 clinical trial in oral mucositis

Bruker introduces new products at Analytica 2012

Idera commences IMO-3100 Phase 2 clinical trial for psoriasis

Promising anti-diabetic substance found in liquorice root

Intervertebral disc repair phase 2 trial update from Mesoblast

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Discover how SciY empowers scientists

Latest Life Science News